+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Treatment of Rituximab plus MVCP chemotherapy in a patient of refractory NHL with AIHA

Treatment of Rituximab plus MVCP chemotherapy in a patient of refractory NHL with AIHA

Blood 102(11): 296b, November 16

Background: Rituximab (a chimeric anti-CD20 antibody), an active agent against B cell malignancies, is not only used for the treatment of B- cell NHL, but also has recently been used for the treatment of the refractory antibody mediated autoimmune diseases such as immune mediated thrombocytopenia and autoimmune hemolytic anemia (AIHA) etc. Method: We have treated successfully a patient of refractory NHL(B -cell IIIB) with AIHA. A 68 years old woman with NHL and AIHA was treated with chemotherapy included COP, COPP, CHOP, BECHOP, MIV, ESHAP etc and radiotherapy for 7 years. The enlargement of superficial and abdominal lymph nodes and anemia is severe before the treatment of Rituximab plus MVCP (Mitoxantrone, Vumon, CTX, Prednison) chemotherapy. The patient has received 3 times infusion of Rituximab (375mg/m2 per dose) in combination with 3 times of MVCP Chemotherapy and rhG-CSF(Lenograstim). Result: The patient achieved complete remission (CR) and Hemoglobin returned to normal after only 1 dose with Rituximab and MVCP chemotherapy. Conclusion: Our result indicate that the treatment of Rituximab combination with MVCP is effective and suitable for refractory NHL (CD 20+) with AIHA.

(PDF emailed within 1 workday: $29.90)

Accession: 035980601

Download citation: RISBibTeXText

Related references

Successful treatment with rituximab in a patient with refractory thrombotic thrombocytopenic purpura refractory to plasma exchange. Japanese Journal of Clinical Hematology 51(2): 127-131, 2010

Durable remission induced by rituximab-containing chemotherapy in a patient with primary refractory Burkitt's lymphoma. Annals of Hematology 83(2): 120-123, 2003

Treatment with Rituximab in acute severe idiopathic AIHA. Blood 102(11): 4b, November 16, 2003

Rituximab provides durable remission in a patient with refractory aggressive diffuse B-cell lymphoma failing salvage chemotherapy. Leukemia & Lymphoma 43(11): 2235-2236, 2003

Treatment of a relapsed radio- and chemotherapy refractory primary CNS lymphoma with rituximab. Onkologie 23(Sonderheft 7): 75, October, 2000

A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. British Journal of Haematology 174(4): 571-581, 2016

Rituximab is an effective and safe treatment of relapse in elderly patients with resistant warm AIHA. Annals of Hematology 95(5): 765-769, 2016

Treatment of patients with relapsed or refractory aggressive non-Hodgkins-lymphoma with rituximab and combination chemotherapy. Onkologie 23(Sonderheft 7): 154, October, 2000

A three-year experience with use of mabthera (rituximab) in treatment of indolent non-Hodgkin's disease refractory to standard chemotherapy. Voprosy Onkologii 50(4): 421-425, 2004

Successful treatment of a patient with refractory Wegener's granulomatosis by rituximab. Nihon Rinsho Men'eki Gakkai Kaishi 30(2): 133-138, 2007

Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy. Haemophilia 13(1): 46-50, 2007

Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab. Transplantation 83(7): 912-918, 2007

Effective treatment with rituximab in a patient with refractory idiopathic thrombocytopenic purpura. Japanese Journal of Clinical Hematology 45(11): 1181-1186, 2004

Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. Journal of Neuro-Oncology 59(3): 213-216, 2002

Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Clinical Lymphoma & Myeloma 7(6): 406-412, 2007